Guildford, UK, 27 July 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it has entered into arrangements pursuant to which ReNeuron will acquire the business assets of AmCyte Inc., a development stage cell therapy company based in Santa Monica, California.
Guildford, UK, 20 July 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it has sent the notice of Annual General Meeting to shareholders. The meeting will take place at 10.00am on 6 September 2007 at the offices of Morrison & Foerster MNP, City Point, One Ropemaker Street, London, EC2Y 9AW.
Operational Highlights
Guildford, UK, 22 June 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it has taken a major step forward with its ReN002 diabetes programme with the generation of new data concerning its pancreatic cell lines for the treatment of Type 1 (juvenile) diabetes. ReNeuron scientists have generated stable human pancreatic cell lines that form islet-like cell clusters. These clusters were shown to secrete insulin in response to glucose concentrations, demonstrating their potential as a cell therapy candidate for Type 1, insulin-dependent, diabetes patients.
Guildford, UK, 15 June 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its preliminary results for the year ending 31 March 2007 on Wednesday 27 June 2007.
Guildford, UK, 15 June 2007: ReNeuron Group plc (LSE: RENE.L) today announces that US-based Millipore Corporation, the exclusive distributor of ReNeuron’s ReNcell®CX and ReNcell®VM neural cell lines, will highlight characteristics of the cell lines in a presentation to be given by Dr Vi Chu, Millipore Bioscience Division, at the 5th International Society for Stem Cell Research (ISSCR) Annual Meeting in Cairns, Australia on 17-20 June. The presentation is scheduled for 08:00 am local time on 20 June.
(http://www.biomedcentral.com/1471-2202/8/36/abstract)
ReNeuron has used its c-mycER technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.
Guildford, UK, 18 May 2007: ReNeuron Group plc (LSE: RENE.L) today announced that it has signed a Research Collaboration Agreement with King’s College London to further develop the Company’s c-mycER stem cell expansion technology. The research will be part-funded by the UK government under its Knowledge Transfer Partnership (KTP) scheme.
Guildford, UK, 10 May 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will be participating in the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference, taking place at The Meridien Beach Plaza Hotel, Monte Carlo, Monaco on 14-15 May.
Michael Hunt, Chief Executive Officer, will give an overview of the Company’s activities in a presentation scheduled for 3:15pm local time on 15 May. The presentation will be webcast and available for viewing via the conference website or via the Company’s website at www.reneuron.com.
Guildford, UK, 1 May 2007: ReNeuron Group plc (LSE: RENE.L) today announces that it will be participating in the 2nd European Stem Cells and Regenerative Medicine Congress, taking place at The Landmark Hotel, London on 1-3 May. Michael Hunt, Chief Executive Officer, will present ReNeuron as a case study in the stem cell commercialisation session on the afternoon of 2
May.
